Jacob Keane-Candib

Jacob Keane-Candib

Auto-generated profile, based on publicly available information

Jacob Keane-Candib

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
CWCarla S. Walti
Carla S. Walti
EKElizabeth Krantz
Elizabeth Krantz
JMJoyce Maalouf
Joyce Maalouf
JBJim Boonyaratanakornkit
Jim Boonyaratanakornkit
JKJacob Keane-Candib
Jacob Keane-Candib
JHJoshua aiden Hill
Joshua aiden Hill
BACKGROUND: Little is known about pathogen-specific humoral immunity after chimeric antigen receptor–modified T (CAR-T) cell therapy for B cell malignancies. METHODS: We conducted a prospective cross-sectional study of CD19-targeted or B cell maturation antigen–targeted (BCMA-targeted) CAR-T cell therapy recipients at least 6 months posttreatment and in remission. We measured pathogen-specific IgG against 12 vaccine-preventable infections and the number of viral and bacterial epitopes to which IgG was detected (“epitope hits”) using a serological profiling assay. The primary outcome was the proportion of participants with IgG levels above a threshold correlated with seroprotection for vaccine-preventable infections. RESULTS: We enrolled 65 children and adults a median of 20 months after CD19- ( n = 54) or BCMA- ( n = 11) CAR-T cell therapy. Among 30 adults without IgG replacement therapy (IGRT) in the prior 16 weeks, 27 (90%) had hypogammaglobulinemia. These individuals had seroprotection to a median of 67% (IQR, 59%–73%) of tested infections. Proportions of participants with seroprotection per pathogen were comparable to population-based studies, but most individuals lacked seroprotection to specific pathogens. Compared with CD19-CAR-T cell recipients, BCMA-CAR-T cell recipients were half as likely to have seroprotection (prevalence ratio, 0.47; 95% CI, 0.18–1.25) and had fewer pathogen-specific epitope hits (mean difference, –90 epitope hits; 95% CI, –157 to –22). CONCLUSION: Seroprotection for vaccine-preventable infections in adult CD19-CAR-T cell recipients was comparable to the general population. BCMA-CAR-T cell recipients had fewer pathogen-specific antibodies. Deficits in both groups support the need for vaccine and immunoglobulin replacement therapy studies. FUNDING: Swiss National Science Foundation (Early Postdoc Mobility grant P2BSP3_188162), NIH/National Cancer Institute (NIH/NCI) (U01CA247548 and P01CA018029), NIH/NCI Cancer Center Support Grants (P30CA0087-48 and P30CA015704-44), American Society for Transplantation and Cellular Therapy, and Juno Therapeutics/BMS.

11 March 2022 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
SJSrirama Josyula
Srirama Josyula
MPMargot J. Pont
Margot J. Pont
SDSayan Dasgupta
Sayan Dasgupta
XSXiaoling Song
Xiaoling Song
STSushma Thomas
Sushma Thomas
JHJoshua aiden Hill
Joshua aiden Hill
Chimeric antigen receptor (CAR) T cells targeting B-cell maturation antigen (BCMA-CARTx) are an emerging treatment for relapsed or refractory multiple myeloma (R/R MM). Characterize the epidemiology of infections, risk factors for infection, and pathogen-specific humoral immunity in patients receiving BCMA-CARTx for R/R MM. We performed a retrospective cohort study in 32 adults with R/R MM enrolled in two single-institution phase 1 clinical trials of BCMA-CARTx administered after lymphodepleting chemotherapy alone (n=22) or with (n=10) a gamma secretase inhibitor (GSI). We tested serum prior to and up to approximately 180 days after BCMA-CARTx for measles-specific IgG and for any viral-specific IgG using a systematic viral epitope scanning assay to describe the kinetics of total and pathogen-specific IgG levels pre- and post-BCMA-CARTx. We identified microbiologically documented infections to determine infection incidence and used Poisson regression to explore risk factors for infections within 180 days after BCMA-CARTx. Most individuals developed severe neutropenia, lymphopenia and hypogammaglobulinemia after BCMA-CARTx. Grade ≥3 cytokine release syndrome (CRS; Lee criteria) occurred in 16% of participants; corticosteroids and/or tocilizumab were administered to 50% of participants. Before BCMA-CARTx, 28/32 (88%) participants had an IgG <400 mg/dL and only 5/27 (19%) had seropositive measles antibody titers. After BCMA-CARTx, all participants had IgG <400 mg/dL and declining measles antibody titers; of the 5 individuals with baseline seropositive levels, 2 remained above the seroprotective threshold post-treatment. Participants with IgG MM (n=13) had significantly fewer antibodies to a panel of viral antigens compared to participants with non-IgG MM (n=6), both prior to and after BCMA-CARTx. In the first 180 days after BCMA-CARTx, 17 (53%) participants developed 23 infections, in whom 13/23 (57%) infections were mild-to-moderate viral infections. Serious infections were more frequent in the first 28 days. Infections appeared to be more common in individuals with higher-grade CRS. Individuals with R/R MM have substantial deficits in humoral immunity. These data demonstrate the importance of plasma cells in maintaining long-lived pathogen-specific antibodies and suggest that BCMA-CARTx recipients should have ongoing surveillance for late-onset infections. Most infections were mild-moderate severity viral infections. The early infection incidence appears to be lower than reported after CD19-CARTx for B-cell neoplasms, which may be due to differences in patient/disease characteristics and regimen related toxicities.

12 January 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
JHJoshua aiden Hill
Joshua aiden Hill
EKErika S. Kiem
Erika S. Kiem
ABAtif Bhatti
Atif Bhatti
WLWinnie Liu
Winnie Liu
JKJacob Keane-Candib
Jacob Keane-Candib
SJShaun W. Jackson
Shaun W. Jackson
Antibodies against foreign human leukocyte antigen (HLA) molecules are barriers to successful organ transplantation. B cell-depleting treatments are used to reduce anti-HLA antibodies but have limited efficacy. We hypothesized that the primary source for anti-HLA antibodies is long-lived plasma cells, which are ineffectively targeted by B cell depletion. To study this, we screened for anti-HLA antibodies in a prospectively enrolled cohort of 49 patients who received chimeric antigen receptor T-cell therapy (CARTx), targeting naïve and memory B cells (CD19-targeted, n = 21) or plasma cells (BCMA-targeted, n = 28) for hematologic malignancies. Longitudinal samples were collected before and up to 1 year after CARTx. All individuals were in sustained remission. We identified 4 participants with anti-HLA antibodies before CD19-CARTx. Despite B cell depletion, anti-HLA antibodies and calculated panel reactive antibody scores were stable for 1 year after CD19-CARTx. Only 1 BCMA-CARTx recipient had pre-CARTx low-level anti-HLA antibodies, with no follow-up samples available. These data implicate CD19neg long-lived plasma cells as an important source for anti-HLA antibodies, a model supported by infrequent HLA sensitization in BCMA-CARTx subjects receiving previous plasma cell-targeted therapies. Thus, plasma cell-targeted therapies may be more effective against HLA antibodies, thereby enabling improved access to organ transplantation and rejection management.

1 March 2021 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
SJSrirama Josyula
Srirama Josyula
MPMargot J. Pont
Margot J. Pont
JKJacob Keane-Candib
Jacob Keane-Candib
XSXiaoling Song
Xiaoling Song
STSushma Thomas
Sushma Thomas
JHJoshua aiden Hill
Joshua aiden Hill